Exscientia plc (EXAI)

5.19 -0.01 (-0.19%) 收市：04:00PM EDT

Exscientia plc

The Schrödinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 18 6581 8941
https://www.exscientia.ai

版塊: Healthcare
行業: Biotechnology
全職員工: 483

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. David Hallett Ph.D.	Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director	無	無	1969
Mr. Ben R. Taylor	CFO, Chief Strategy Officer & Executive Director	534.97k	無	1977
Dr. Michael Krams M.D.	Chief Medical Officer	無	無	1961
Ms. Eileen Jennings-Brown	Chief Information Officer	無	無	無
Ms. Sara Sherman	Vice President of Investor Relations	無	無	無
Mr. Dan Ireland	Executive VP of Legal & Company Secretary	無	無	無
Mr. Parker Moss	Executive Vice President of Corporate Development	無	無	無
Ms. Caroline Rowland	Chief People Officer	無	無	無
Mr. Richard Law	Chief Business Officer	無	無	無
Dr. John P. Overington Ph.D.	Chief Data Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

公司管治

截至 無 止，Exscientia plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。